Century Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.

Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, cancer and Type 1 diabetes. The IPSC news feed on Stock Titan aggregates company announcements, press releases and regulatory updates so readers can follow how Century Therapeutics communicates progress on its pipeline and corporate strategy.

According to the company’s public disclosures, key news themes include updates on clinical and preclinical programs such as CNTY-101 for B-cell-mediated autoimmune diseases, CNTY-308 as a CD19-targeted CAR-iT therapy, and CNTY-813, an iPSC-derived beta islet program for Type 1 diabetes. News items also cover scientific presentations at conferences, where Century Therapeutics shares data on Allo-Evasion™ 5.0, CAR-NK and CAR-T platforms, and iPSC-derived non-immune cell programs.

Investors and followers of IPSC can also find coverage of quarterly financial results, cash runway commentary, and organizational changes such as workforce adjustments, board appointments and executive role updates. Capital markets events, including private placement financings and participation in healthcare investment conferences, are typically disclosed through press releases and associated Form 8-K filings.

By reviewing the IPSC news stream, readers can see how Century Therapeutics describes the evolution of its iPSC cell foundry, its focus on B-cell-mediated diseases and oncology, and its efforts to advance off-the-shelf cell therapies. Bookmark this page to access a consolidated view of Century Therapeutics’ latest public communications as they are released.